City of Hope Becomes 5AM Solution's First Open Source Client
News Jan 20, 2006
5AM Solutions has signed a services agreement with the City of Hope (COH) to support the adoption of the Microarray Enterprise Manager (MEM) as the enterprise solution for COH's Microarray Core Facility.
5AM will modify the source code to run on a completely open source environment. Future efforts will target incorporating the core facility's business processes into the workflow modules.
It also will include investigating the feasibility of having the data management system cover new areas of research such as proteomics, in addition to joint collaborations supporting further development through grants.
Dr. Yate-Ching Yuan, Manager for the Department of Biomedical Informatics at COH, said, "We are excited about our collaboration with 5AM and the power of the software to help us apply our expertise, adopt our business processes, and serve our research community."
Dr. Richard Jove, Deputy Director of the City of Hope Comprehensive Cancer Center, said, "This is an important collaboration among 5AM, TGen and City of Hope, bringing together leading experts on molecular analysis of tumors, which will ultimately benefit cancer patients with improved treatment."
After a thorough evaluation of the competition, MEM was chosen due to its ability to integrate directly with the Affymetrix platform, the scientific contributions from a wide range of experts in the field who guided its development, the ability to produce and validate MIAME compliance, and the open source option and services provided by 5AM.
Originally developed for an NIH-sponsored national microarray consortium, 5AM produced an open source version in October 2005.
5AM CEO Brent Gendleman said, "We are excited by the opportunity to extend our services to such a distinguished research institute as the City of Hope and continue to improve our offerings of solutions to the life science community."
MEM is designed to orchestrate consistent data annotations that meet evolving industry standards for projects, samples, and the derivative microarray data.
Dr. Dietrich Stephan, Chairman of the consortium and Director of the Neurogenomics Division of TGen, said, "This solution results in improvements of experiment design, reproducibility, and the public sharing of meaningful information."
"5AM worked with our leaders, lab scientists, and bioinformaticians intimately to translate our vision into reality. We are excited to see the software evolve to support other institutes"
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.